Clinical failure of botulinum toxin A in movement disorders

Rodolfo Savica, Brandon R. Grossardt, James Howard Bower, Bryan Klassen, Joseph Y. Matsumoto

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

Objective: Botulinum toxin (BTX) injections have been used extensively in medicine; however, little is known about the factors predicting the loss of effectiveness of botulin toxin. Methods: Using a clinical database, we identified 401 subjects who had been treated for movement disorders from 1998 through 2010 with onabotulinumtoxin A (BTX A) or who switched from BTX A to rimabotulinumtoxin B (BTX B). We compared patients who switched from type A to type B with patients using type A only with regard to number of visits, total number of injections, number of initial and final sites, number of initial units used, and duration of treatments. Results: We observed that patients who switched from BTX A to B had a significantly higher number of initial injection sites than patients with BTX A only (BTX A to B median=8.5; BTX A median=6; p for difference=0.006), had a higher number of final sites (BTX A to B median=9 BTX A median=7; p=0.01), and were also more likely to have multiple reasons for injection (BTX A to B=25.0%; botulin toxin A=5.3%; p=0.01). We did not find significant differences between groups based on the other variables. Conclusions: Our findings suggest that higher number of sites rather than higher number of units or years of treatment are associated with the loss of effectiveness to BTX A. It is possible that the loss of effectiveness to the BTX is more strongly elicited when the injections are widely diffuse.

Original languageEnglish (US)
Pages (from-to)73-75
Number of pages3
JournalParkinsonism and Related Disorders
Volume18
Issue number1
DOIs
StatePublished - Jan 2012

Fingerprint

Type A Botulinum Toxins
Movement Disorders
Botulinum Toxins
Injections
Medicine
Databases

Keywords

  • Botulin toxin
  • Cervical dystonia
  • Hemifacial spasm
  • Torticollis

ASJC Scopus subject areas

  • Geriatrics and Gerontology
  • Clinical Neurology
  • Neurology

Cite this

Clinical failure of botulinum toxin A in movement disorders. / Savica, Rodolfo; Grossardt, Brandon R.; Bower, James Howard; Klassen, Bryan; Matsumoto, Joseph Y.

In: Parkinsonism and Related Disorders, Vol. 18, No. 1, 01.2012, p. 73-75.

Research output: Contribution to journalArticle

@article{dc933e07545b4ace82fe8c2c0ff7e2a7,
title = "Clinical failure of botulinum toxin A in movement disorders",
abstract = "Objective: Botulinum toxin (BTX) injections have been used extensively in medicine; however, little is known about the factors predicting the loss of effectiveness of botulin toxin. Methods: Using a clinical database, we identified 401 subjects who had been treated for movement disorders from 1998 through 2010 with onabotulinumtoxin A (BTX A) or who switched from BTX A to rimabotulinumtoxin B (BTX B). We compared patients who switched from type A to type B with patients using type A only with regard to number of visits, total number of injections, number of initial and final sites, number of initial units used, and duration of treatments. Results: We observed that patients who switched from BTX A to B had a significantly higher number of initial injection sites than patients with BTX A only (BTX A to B median=8.5; BTX A median=6; p for difference=0.006), had a higher number of final sites (BTX A to B median=9 BTX A median=7; p=0.01), and were also more likely to have multiple reasons for injection (BTX A to B=25.0{\%}; botulin toxin A=5.3{\%}; p=0.01). We did not find significant differences between groups based on the other variables. Conclusions: Our findings suggest that higher number of sites rather than higher number of units or years of treatment are associated with the loss of effectiveness to BTX A. It is possible that the loss of effectiveness to the BTX is more strongly elicited when the injections are widely diffuse.",
keywords = "Botulin toxin, Cervical dystonia, Hemifacial spasm, Torticollis",
author = "Rodolfo Savica and Grossardt, {Brandon R.} and Bower, {James Howard} and Bryan Klassen and Matsumoto, {Joseph Y.}",
year = "2012",
month = "1",
doi = "10.1016/j.parkreldis.2011.07.016",
language = "English (US)",
volume = "18",
pages = "73--75",
journal = "Parkinsonism and Related Disorders",
issn = "1353-8020",
publisher = "Elsevier BV",
number = "1",

}

TY - JOUR

T1 - Clinical failure of botulinum toxin A in movement disorders

AU - Savica, Rodolfo

AU - Grossardt, Brandon R.

AU - Bower, James Howard

AU - Klassen, Bryan

AU - Matsumoto, Joseph Y.

PY - 2012/1

Y1 - 2012/1

N2 - Objective: Botulinum toxin (BTX) injections have been used extensively in medicine; however, little is known about the factors predicting the loss of effectiveness of botulin toxin. Methods: Using a clinical database, we identified 401 subjects who had been treated for movement disorders from 1998 through 2010 with onabotulinumtoxin A (BTX A) or who switched from BTX A to rimabotulinumtoxin B (BTX B). We compared patients who switched from type A to type B with patients using type A only with regard to number of visits, total number of injections, number of initial and final sites, number of initial units used, and duration of treatments. Results: We observed that patients who switched from BTX A to B had a significantly higher number of initial injection sites than patients with BTX A only (BTX A to B median=8.5; BTX A median=6; p for difference=0.006), had a higher number of final sites (BTX A to B median=9 BTX A median=7; p=0.01), and were also more likely to have multiple reasons for injection (BTX A to B=25.0%; botulin toxin A=5.3%; p=0.01). We did not find significant differences between groups based on the other variables. Conclusions: Our findings suggest that higher number of sites rather than higher number of units or years of treatment are associated with the loss of effectiveness to BTX A. It is possible that the loss of effectiveness to the BTX is more strongly elicited when the injections are widely diffuse.

AB - Objective: Botulinum toxin (BTX) injections have been used extensively in medicine; however, little is known about the factors predicting the loss of effectiveness of botulin toxin. Methods: Using a clinical database, we identified 401 subjects who had been treated for movement disorders from 1998 through 2010 with onabotulinumtoxin A (BTX A) or who switched from BTX A to rimabotulinumtoxin B (BTX B). We compared patients who switched from type A to type B with patients using type A only with regard to number of visits, total number of injections, number of initial and final sites, number of initial units used, and duration of treatments. Results: We observed that patients who switched from BTX A to B had a significantly higher number of initial injection sites than patients with BTX A only (BTX A to B median=8.5; BTX A median=6; p for difference=0.006), had a higher number of final sites (BTX A to B median=9 BTX A median=7; p=0.01), and were also more likely to have multiple reasons for injection (BTX A to B=25.0%; botulin toxin A=5.3%; p=0.01). We did not find significant differences between groups based on the other variables. Conclusions: Our findings suggest that higher number of sites rather than higher number of units or years of treatment are associated with the loss of effectiveness to BTX A. It is possible that the loss of effectiveness to the BTX is more strongly elicited when the injections are widely diffuse.

KW - Botulin toxin

KW - Cervical dystonia

KW - Hemifacial spasm

KW - Torticollis

UR - http://www.scopus.com/inward/record.url?scp=84655169226&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84655169226&partnerID=8YFLogxK

U2 - 10.1016/j.parkreldis.2011.07.016

DO - 10.1016/j.parkreldis.2011.07.016

M3 - Article

C2 - 21880538

AN - SCOPUS:84655169226

VL - 18

SP - 73

EP - 75

JO - Parkinsonism and Related Disorders

JF - Parkinsonism and Related Disorders

SN - 1353-8020

IS - 1

ER -